Lv1
28 积分 2025-08-19 加入
SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial
19天前
已完结
Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors
19天前
已完结
Polymeric rapamycin nanoparticles encapsulating ponatinib cause regression of venous malformations in mice
1个月前
已完结
Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors
1个月前
已完结
Constitutive, Mosaic Expression of TIE2 p.L914F During Mouse Development Causes Venous Malformation
1个月前
已完结
EZH1/2 Dual Inhibitor Valemetostat Tosylate (DS-3201b) Acts Differently from EZH2 Selective Inhibitor on Epigenetic Landscape to Exert Greater Anti-Tumor Effect Against Diffuse Large B-Cell Lymphoma
3个月前
已关闭
EZH2 serves as a promising therapeutic target for fibrosis
5个月前
已完结
Therapies in autosomal dominant polycystic kidney disease: beyond tolvaptan
5个月前
已完结
Culture of Three-Dimensional Madin–Darby Canine Kidney (MDCK) Cysts for In Vitro Drug Testing in Polycystic Kidney Disease
5个月前
已完结
OPC-41061, a Highly Potent Human Vasopressin V2-Receptor Antagonist: Pharmacological Profile and Aquaretic Effect by Single and Multiple Oral Dosing in Rats
5个月前
已完结
皖公网安备34019202002308
